Introduction {#Sec1}
============

Globally, colorectal cancer (CRC) is one of the leading causes of tumour-associated deaths \[[@CR1]\]. A major determinant of outcome is the extent of disease. Patients with metastatic (Stage IV) disease have a 5-year survival rate of 12 % compared with 90 % for Stage I/II and 70 % for Stage III disease \[[@CR2]\]. Twenty-five to 50 % of patients with CRC present with liver metastases, either synchronous or metachronous (at a later stage), after the initial diagnosis of the primary tumour \[[@CR3]\]. Surgery can achieve cure in both hepatic and extrahepatic metastatic disease, provided that all of the tumour can be resected. Overall 5-year survival ranges between 16 % and 74 % after liver resection for hepatic colorectal metastasis \[[@CR4]\]. Hepatic recurrence can be expected in 50--60 % of patients with hepatic metastases \[[@CR5]--[@CR7]\].

Surgical strategy in patients scheduled for liver resection is based on pre-operative imaging with a variety of modalities, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound (US) and positron emission tomography (PET) or PET-CT. The final assessment of the extent of the disease, however, is made during the operation by surgical exploration of the liver and intra-operative ultrasound. Deviation from the pre-operative surgical plan due to additional intra-operative findings is undesirable and can potentially lead to increased costs.

MRI has been demonstrated to be the best imaging method for detection and characterization of focal liver lesions \[[@CR8]--[@CR10]\]. The detection and characterization capabilities of MRI can be enhanced further by using hepatobiliary contrast agents like gadoxetic-acid (gadolinium ethoxybenzyl-diethylenetriamine-penta-acetate; Gd-EOB-DTPA) \[[@CR11]--[@CR18]\]. The VALUE study, a prospective, randomized trial that compared Gd-EOB-DTPA-MRI, MRI with extracellular contrast media (ECCM-MRI) and contrast-enhanced multiple detector CT (CE-MDCT) for hepatic staging of patients with suspected or confirmed metachronous CRC-liver metastases (CRCLM), has recently been published \[[@CR19]\]. The VALUE study showed that patients randomized to initial diagnostic imaging with Gd-EOB-DTPA-MRI needed significantly fewer additional imaging procedures for a confident diagnosis and treatment decision, compared to those randomized to ECCM-MRI or CE-MDCT as initial imaging modality. Furthermore, Gd-EOB-DTPA-MRI imaging yielded a significantly higher confidence in the diagnosis and treatment plan compared to the other two modalities. The information provided by Gd-EOB-DTPA-MRI resulted in a decreased number of patients with intra-operative modifications of the surgical plan in patients undergoing liver resection.

The economic implications of the medical benefits of initial imaging with Gd-EOB-DTPA-MRI observed for patients in this clinical scenario, however, remain to be determined. Thus, the purpose of this within-trial cost evaluation of the VALUE study was to assess the comparative costs of diagnostic workup and surgery of the three strategies; i.e. initial imaging with Gd-EOB-DTPA-MRI, ECCM-MRI or CE-MDCT in patients with suspected CRCLM.

Materials and methods {#Sec2}
=====================

This within-trial cost evaluation of the VALUE study was based on data for 360 patients with known or suspected metachronous liver metastases secondary to colorectal cancer who were scheduled for further contrast-enhanced tomographic imaging, who were randomized to one of the three initial imaging techniques. The randomization list was developed by a biometrician. The final randomization code was generated using the validated program RANDOM as 1 : 1 : 1 randomization (block size 6). The randomization list included the randomization codes, patient identifier and assigned imaging modality. The randomization information was provided in sealed envelopes that were kept securely in the radiology department at each study site. Patients were recruited from eight countries (Switzerland N = 3; Sweden N = 4; Italy N = 13; Spain N = 16; Thailand N = 62; Austria N = 77, Germany N = 83 and Korea N = 102). The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines, following approval by relevant ethics committees/institutional review boards at the participating centres. All patients gave their written informed consent to participate in the study.

Six patients did not receive any treatment or contrast agent in the study and were dropouts (screening failures). All patients who received any amount of contrast medium were included in the safety population (N = 354). Population characteristics as well as safety analyses were performed using all available data from those patients. All patients who received a contrast medium, for whom the primary parameter was available and who had no major protocol deviation, were included in the efficacy population (N = 342).

Whenever possible, the analyses in this manuscript were made on the safety population. Some data presented in this paper differ slightly from those in the article describing the clinical results of the VALUE study \[[@CR19]\], where most of the analyses were performed on the efficacy population.

The safety population was as follows: 122 had initial imaging with Gd-EOB-DTPA-MRI, 116 with ECCM-MRI and 116 with CE-MDCT. For some homogeneity analyses, however, the efficacy population consisting of 342 patients was used since some of the variables tested were only measured for those patients who completed the study. This trial-based cost analysis was programmed as a decision-tree (using TreeAge Pro 2009), designed to mirror the outline of a model-based health-economic approach published previously \[[@CR20]\] and populated with actual clinical data from the VALUE study \[[@CR19]\]. An overview of the decision tree is given in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Outline of the cost-evaluation model

Transition probabilities {#Sec3}
------------------------

After the initial imaging procedure, the first consensus meeting consisting of the local investigators (liver surgeon and radiologist, and in some instances also an oncologist according to local practice) was held to decide whether a confident treatment decision could be made or if further imaging was required to come to a therapy decision. The consensus group was aware of the intent of the study and that a health-economic evaluation was planned after publishing the primary study results. If further imaging was required, the interdisciplinary team (as specified above) was free to choose one of the two remaining imaging modalities, followed by another interdisciplinary team meeting. After pre-treatment imaging (one or two modalities), a treatment plan was drafted with patients with potentially operable disease being referred for surgical intervention. In patients deemed operable, a detailed operation plan was drafted. The probabilities for 'further imaging required' were calculated from the patient-level data as the proportion of patients who required a second imaging procedure (Table [1](#Tab1){ref-type="table"}).Table 1Diagnostic workup, transition probabilities, number of patients and percentage of those who received a first imaging in each groupInitial imagingCE-MDCTECCM-MRIGd-EOB-DTPA-MRIFurther imaging required?No further imaging70 (60.3 %)95 (81.9 %)122 (100.0 %)Further imaging required46 (39.7 %)21 (18.1 %)0 (0.0 %) Second imaging with CE-CT0 (0.0 %)0 (0.0 %)- Second imaging with ECCM-MRI1 (2.2 %)0 (0.0 %)- Second imaging with Gd-EOB-DTPA-MRI45 (97.8 %)21 (100.0 %)-Total116 (100.0 %)116 (100.0 %)122 (100.0 %)*CE-MDCT* contrast-enhanced MDCT, *ECCM-MRI* MRI with extracellular contrast-media, *Gd-EOB-DTPA-MRI* gadoxetic-acid-enhanced MRI, *MRI* magnetic resonance imaging, *CT* computed tomography, *MDCT* multiple detector CT

In total, 115 patients were assessed as being primarily resectable, i.e. could be rendered tumour free by one operative intervention (surgery with/without concomitant local ablation) without the necessity of pre-operative tumour or volume manipulation by down-staging chemotherapy or portal-vein embolization. During surgery, it was documented whether the operation resulted in liver resection and whether the pre-operative surgical plan was executed unchanged or modified due to additional intra-operative findings. Among patients for whom the surgical plan was modified during surgery, the probability of having a longer intervention was estimated and the difference in surgery time due to modification of the surgical plan was recorded. The difference in surgery time was intended to judge the estimated amount of additional planning time, and not the increase in the procedural time itself.

Finally, the probabilities of modification of the surgical plan resulting in no resection during surgery (i.e. undergoing non-therapeutic intervention, hereafter referred to as 'unnecessary surgery') were estimated from the patient-level VALUE data. These transition probabilities are presented in Table [2](#Tab2){ref-type="table"}. Transition probabilities and resource use were always estimated for the pooled patient population, and not stratified by country. As such, the sample size was the same for all countries, so that the differences in patients included per country did not have an effect on the country-specific evaluation later on.Table 2Surgery and surgical plan, transition probabilities based on the safety population (number of patients and percentage of those who receive a first imaging in each group)Imaging sequenceInitial CE-MDCTInitial ECCM-MRIInitial Gd-EOB-DTPA-MRIOnly CE-MDCTCE-MDCT + ECCM-MRICE-MDCT + Gd-EOB-DTPA-MRITotal starting with CE-CTOnly ECCM-MRIECCM-MRI + Gd-EOB-DTPA-MRITotal starting with ECCM-MRIOnly Gd-EOB-DTPA-MRISelected for surgery?Surgery17 (24.3 %)0 (0.0 %)14 (31.1 %)31 (26.7 %)25 (26.3 %)11 (52.4 %)36 (31.0 %)48 (39.3 %)No surgery53 (75.7 %)1 (100.0 %)31 (68.9 %)85 (73.3 %)70 (73.7 %)10 (47.6 %)80 (69.0 %)74 (60.7 %)Total701451169521116122If selected, surgical Plan confirmed?Confirmed surgical plan9 (52.9 %)-12 (85.7 %)21 (67.7 %)16 (64.0 %)8 (72.7 %)24 (66.7 %)32 (66.7 %)Modified surgical plan8 (47.1 %)-2 (14.3 %)10 (32.3 %)8 (32.0 %)2 (18.2 %)10 (27.8 %)15 (31.3 %)No resection (unnecessary surgery)0 (0.0 %)-0 (0.0 %)0 (0.0 %)1 (4.0 %)1 (9.1 %)2 (5.6 %)1 (2.1 %)Total170143125113648If modified, surgery was prolonged?Prolonged surgery5 (62.5 %)-0 (0.0 %)5 (50.0 %)4 (50.0 %)1 (50.0 %)5 (50.0 %)7 (46.7 %)Surgery not prolonged3 (37.5 %)-2 (100.0 %)5 (50.0 %)4 (50.0 %)1 (50.0 %)5 (50.0 %)8 (53.3 %)Total8210821015*CE* contrast-enhanced, *CE-MDCT* contrast-enhanced MDCT, *ECCM-MRI* MRI with extracellular contrast-media, *Gd-EOB-DTPA-MRI* gadoxetic-acid-enhanced MRI, *MRI* magnetic resonance imaging, *CT* computed tomography, *MDCT* multiple detector CT

Resource utilization and cost {#Sec4}
-----------------------------

A payer perspective was adopted for the cost analysis with Germany as the base case. Analyses were then conducted for the remaining countries participating in the trial: Austria, Italy, Korea, Spain, Sweden, Switzerland and Thailand. Unit costs collected for these countries were multiplied by the resource utilization of the pooled population for a cross-country comparison (unit costs and references are presented in Supplemental Table [1](#MOESM1){ref-type="media"}).

The VALUE data contained the following detailed patient-level information on resource utilization: (a) contrast agents used for the imaging, (b) length of surgery, (c) estimated additional length of surgery in case of a modified surgical plan, (d) number of days of intensive care following surgery and (e) number of days of standard in-hospital care following surgery.

The total cost of diagnostic workup in each group was calculated as: \[cost of imaging procedure without contrast + cost of contrast media expressed as the weighted average of substances used in the VALUE trial + cost of a consensus meeting(s)\]. The list of contrast agents, their weights and costs are presented in Supplemental Table [1](#MOESM1){ref-type="media"}. The cost of the consensus meeting was estimated in consultation with clinical experts in each country, following local practices. In some countries, it consisted of a surgeon and radiologist while in others an oncologist was also involved (Supplemental Table [2](#MOESM2){ref-type="media"}). The aim of this approach was to obtain cost estimates mirroring the VALUE trial that would be applicable to each country's clinical routines.

The cost of planned surgery was calculated as: \[surgery time\*cost per minute of surgery under anaesthesia + days in intensive care\*cost per day in intensive care + days in standard care\*cost per day in standard care\]. The additional cost of prolonged surgery was calculated as: \[mean additional length of surgery \*cost per minute of surgery under anaesthesia\]. The resource use (minutes of surgery and days in hospital) was calculated as the total means across all imaging sequences. The resource use was calculated separately for resected and unresected patients (Table [3](#Tab3){ref-type="table"}), based on the assumption that the length of surgery and the days spent in hospital would be different for patients with surgery but without any resection and those with surgery and liver metastases resection.Table 3Resource utilization for patients who underwent surgeryResource useResected patients (N = 112)Unresected patients (N = 3)Average number of minutes of surgery per patient (range)240 (88--700)163 (128--205)Average number of hospitalization days in standard care per patient (range)12.4 (0--104)21.3 (10--38)Average number of hospitalization days in intensive care per patient (range)2.6 (0--42)7.3 (0--17)

Statistical analysis {#Sec5}
--------------------

Homogeneity chi-square tests were performed to test for randomization bias with regard to age and disease severity as measured by (a) presence of non-assessable lesions, (b) presence of assessable lesions, (c) number of affected segments, and (d) total number of lesions. Following cost estimation, one-way sensitivity analyses were performed by systematically varying one input value at a time (values \[prices and probabilities\] were varied by ±5 %) and observing the impact of that change on the results. Sensitivity analyses were performed on the base case, i.e. using 2013 German unit costs. In addition, three alternate scenarios were included.

The first alternative scenario was 'No avoided surgery due to missing additional information of second imaging in the CE-MDCT group'. This scenario was chosen based on five patients in the CE-MDCT group, for whom unnecessary surgery was avoided as the result of a secondary imaging (four cases with Gd-EOB-DTPA-MRI group and one case with ECCM-MRI). The second scenario was 'Unresectable patients recognized before surgery'. In this scenario, two patients who were unresectable because of extrahepatic disease burden were assumed to have been classified as unresectable from the beginning (a second advanced primary tumour of the sigmoid colon in a patient in the Gd-EOB-DTPA-MRI group and extrahepatic growth and peritoneal metastases in a patient in the ECCM-MRI group). In the third scenario, it was assumed that the probability for selection for surgery was equal in all three groups (32.5 %; representative of the 115 patients out of 354 in the whole dataset who were selected for surgery). This third scenario corrects for the impact of more patients being selected for surgery in the Gd-EOB-DTPA-MRI group relative to the other two groups.

All statistical analyses were done in Stata version 10.0.

Results {#Sec6}
=======

Homogeneity analysis {#Sec7}
--------------------

The imaging strategy starting with Gd-EOB-DTPA-MRI detected CRCLM in significantly more patients compared to ECCM-MRI or CE-MDCT (85/118 (70.0 %), 72/112 (64.3 %) and 66/112 (58.9 %), respectively \[P \< 0.0001, Fisher's exact test (pairwise)\]). Moreover, more patients diagnosed with liver metastases in the Gd-EOB-DTPA-MRI group were assessed as eligible for surgery (39.3 % (48/122) vs. 31 % (36/116) and 26.7 % (31/116) in the ECCM-MRI and CE-MDCT groups, respectively). The results of the homogeneity analysis are presented in Supplemental Table [3](#MOESM3){ref-type="media"}: randomization bias between the groups with regard to patients' age or disease severity as measured by the different proxies evaluated could be ruled out between the three groups.

Cost of diagnostic workup {#Sec8}
-------------------------

Costs for diagnostic workup and surgery for the three strategies are summarized in Table [4](#Tab4){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. Initial imaging with Gd-EOB-DTPA-MRI resulted in cost savings compared to ECCM-MRI in all countries except Thailand where the difference was less than 2 %. Compared to CE-MDCT, initial imaging with Gd-EOB-DTPA-MRI was less costly in all countries, except Korea and Spain, where the differences were 4 % and 8 %, respectively. These results are explained by the significant difference in the need for additional imaging procedures (Fig. [3](#Fig3){ref-type="fig"}).Table 4Costs of diagnostic workup and surgery, and cost difference in the different countries (expected per-patient cost in € 2013)Cost itemAustriaGermanyItalyKoreaSpainSwedenSwitzerlandThailandCost breakdown of the strategy starting with Gd-EOB-DTPA-MRICost of diagnostic workup3374032672766921636564381Cost of planned resection6,0413,0197,6342,1177,1316,9147,0804,683Additional cost due to modified surgical procedures1818149141445359140Cost of unnecessary surgery2651291958417528426371Total cost6,6613,5688,2442,4918,1428,8867,9665,275Total cost excluding cost of planned resection6205496103741,0111,972886592Cost breakdown of the strategy starting with CE-MDCTCost of diagnostic workup6034213792666402,259657400Cost of planned resection4,1962,0975,3031,4714,9544,8034,9193,253Additional cost due to modified surgical procedures1313112111084044105Cost of unnecessary surgery00000000Total cost4,8132,5325,7941,7475,7027,10256203,759Total cost excluding cost of planned resection6174354912767482,299701506Cost breakdown of the strategy starting with ECCM-MRICost of diagnostic workup4054053772947232,082595374Cost of planned resection4,6002,2995,8131,6125,4315,2655,3923,566Additional cost due to modified surgical procedures1313111111084044105Cost of unnecessary surgery555269407176365593549147Total cost5,5732,9866,7092,0926,6277,9806,5804,193Total cost excluding cost of planned resection9736878964801,1962,7151,188627Comparison of cost of diagnostic workupGd-EOB-DTPA-MRI minus CE-MDCT−266−18−1121052−623−93-19Gd-EOB-DTPA-MRI minus ECCM-MRI−68−2−110−18−31−446−317Comparison of costs of planned resectionGd-EOB-DTPA-MRI minus CE-MDCT1,8459222,3316462,1772,1112,1611,430Gd-EOB-DTPA-MRI minus ECCM-MRI1,4417201,8215051,7001,6491,6881,117Comparison of additional costs due to modified proceduresGd-EOB-DTPA-MRI minus CE-MDCT5537336131535Gd-EOB-DTPA-MRI minus ECCM-MRI5538336131535Comparison of costs of unnecessary surgeryGd-EOB-DTPA-MRI minus CE-MDCT2651291958417528426371Gd-EOB-DTPA-MRI minus ECCM-MRI−290−140−212−92−190−309−286−76Comparison of total cost of surgeryGd-EOB-DTPA-MRI minus CE-MDCT2,1151,0562,5637332,3882,4082,4391,536Gd-EOB-DTPA-MRI minus ECCM-MRI1,1565851,6474161,5461,3531,4171,076Comparison of total costsGd-EOB-DTPA-MRI minus CE-MDCT1,84810362,4507442,4401,7842,3461,516Gd-EOB-DTPA-MRI minus ECCM-MRI1,0885821,5353991,5159061,3861,082Comparison of total costs excluding planned resectionGd-EOB-DTPA-MRI minus CE-MDCT311411998263−32718586Gd-EOB-DTPA-MRI minus ECCM-MRI−353−138−286−106−185−743−302−35*CE* contrast-enhanced, *CE-MDCT* contrast-enhanced MDCT, *ECCM-MRI* MRI with extracellular contrast-media, *Gd-EOB-DTPA-MRI* gadoxetic-acid-enhanced MRI, *MRI* magnetic resonance imaging, *CT* computed tomography, *MDCT* multiple detector CT Fig. 2Cost of diagnostic workup (ratio relative to Gd-EOB-DTPA-MRI) per country. Please note that the transition probabilities and resource use were always estimated for the pooled patient population, and not stratified by country. *Gd-EOB-DTPA-MRI* gadoxetic-acid-enhanced MRI Fig. 3Further imaging required, percentage of patients

Cost of surgery {#Sec9}
---------------

The results of the additional cost of surgery associated with the three imaging strategies are also presented in Table [4](#Tab4){ref-type="table"}. In addition to the cost of the planned surgical procedure, the consequences of each diagnostic strategy regarding surgery were measured by two secondary outcomes: the costs accrued by intra-operative modification of pre-operative surgical plans and the costs of surgery where no resection was performed (unnecessary surgery). The additional length of surgery due to a modified surgical plan ranged from 20--120 min (median 45 min; mean 49 min). No resection was performed in three patients who underwent surgery.

The cost of surgery was higher in the Gd-EOB-DTPA-MRI group (as significantly more patients underwent surgery), resulting in higher total costs accrued by these patients as a group. However, when the cost consequences (excluding the cost of the planned surgery) were evaluated, initial imaging with Gd-EOB-DTPA-MRI was less expensive than the strategy starting with ECCM-MRI across all countries, but was more expensive than starting with CE-MDCT across all countries, except Sweden where starting with Gd-EOB-DTPA-MRI was the least costly alternative (Table [4](#Tab4){ref-type="table"}).

Sensitivity analysis and alternative scenarios {#Sec10}
----------------------------------------------

The results of the one-way sensitivity analysis and of three alternative scenarios are presented in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}. Sensitivity analysis showed that the cost of liver surgery for resected patients was the main driver for total cost. In the first alternative scenario ('No avoided surgery due to missing additional information of second imaging in the CE-MDCT group'), if patients with missing information had not undergone the second imaging and instead had unnecessary surgery, they would have generated costs as depicted in Table [5](#Tab5){ref-type="table"}. While the total costs are still higher in the strategy starting with Gd-EOB-DTPA-MRI than starting with CE-MDCT, the difference decreased from €1,036 to €465 per patient. In the second scenario ('Unresectable patients recognized before surgery'), the total cost difference between Gd-EOB-DTPA-MRI and ECCM-MRI remained almost unchanged, whereas the difference between Gd-EOB-DTPA-MRI and CE-MDCT decreased by approximately 6 %. In the third scenario ('Assumed that the probability for selection for surgery was equal in all three groups'), the total cost differences between all three strategies were negligible.Table 5One-way sensitivity analysis of cost differences between Gd-EOB-DTPA-MRI and CE-MDCT (€ 2013), base case GermanyScenarioCost difference (Gd-EOB-DTPA-MRI minus CE-MDCT)Total cost (€, 2013)Cost of planned resectionCost of diagnostic workup + Cost of modified/unnecessary surgeryBase case1,036922114CE − MDCT probability of further imaging −5 %1,01992297CE − MDCT probability of further imaging +5 %1,053922131CE − MDCT probability of modified surgery −5 %1,037922115CE − MDCT probability of modified surgery +5 %1,036922114Gd − EOB − DTPA − MRI probability of cancelled resection −5 %1,033922111Gd − EOB − DTPA − MRI probability of cancelled resection +5 %1,039922117Cost of Gd − EOB − DTPA − MRI − 5 %1,024922102Cost of Gd − EOB − DTPA − MRI +5 %1,049922127Cost of CE − MDCT −5 %1,050922128Cost of CE − MDCT +5 %1,023922101Cost of liver surgery, resected patients −5 %990876114Cost of liver surgery, resected patients +5 %1,083968115Cost of liver surgery, unresected patients −5 %1,030922108Cost of liver surgery, unresected patients +5 %1,043922121Cost of prolonged surgery −5 %1,036922114Cost of prolonged surgery +5 %1,037922115No avoided unnecessary surgery due to additional information of second imaging in CE − MDCT group4651,006−541Unresectable patients recognized before surgery972987−15Same probability of surgery in each group\*32−5385\*Here the probability of being selected for surgery was 0.325 (32.5 %) in all arms since 115 patients out of 354 in the whole dataset were selected for surgery*CE* contrast-enhanced, *CE-MDCT* contrast-enhanced MDCT, *ECCM-MRI* MRI with extracellular contrast-media, *Gd-EOB-DTPA-MRI* gadoxetic-acid-enhanced MRI, *MRI* magnetic resonance imaging, *CT* computed tomography, *MDCT* multiple detector CT Table 6One-way sensitivity analysis of cost differences between Gd-EOB-DTPA-MRI and ECCM-MRI (€ 2013), base case GermanyScenarioCost difference (Gd-EOB-DTPA-MRI minus ECCM-MRI)Total cost (€, 2013)Cost of planned resectionCost of diagnostic workup + Cost of modified/unnecessary surgeryBase case582720−138ECCM − MRI probability of further imaging −5 %607720−113ECCM − MRI probability of further imaging +5 %557720−163ECCM − MRI probability of modified surgery −5 %582720−138ECCM − MRI probability of modified surgery +5 %581720−139Gd − EOB − DTPA − MRI probability of cancelled resection −5 %579720−141Gd − EOB − DTPA − MRI probability of cancelled resection +5 %585720−135Gd − EOB − DTPA − MRI −5 %566720−154Cost of Gd − EOB − DTPA − MRI +5 %598720−122Cost of ECCM − MRI −5 %598720−122Cost of ECCM − MRI +5 %565720−155Cost of liver surgery, resected patients −5 %546684−138Cost of liver surgery, resected patients +5 %618756−138Cost of liver surgery, unresected patients −5 %589720−131Cost of liver surgery, unresected patients +5 %575720−145Cost of prolonged surgery −5 %582720−138Cost of prolonged surgery +5 %582720−138Unresectable patients recognized before surgery585717−132Same probability of surgery in each group\*−73−72−145\*Here the probability of being selected for surgery was 0.325 (32.5 %) in all groups since 115 patients out of 354 in the whole dataset were selected for surgery*CE* contrast-enhanced, *CE-MDCT* contrast-enhanced MDCT, *ECCM-MRI* MRI with extracellular contrast-media, *Gd-EOB-DTPA-MRI* gadoxetic-acid-enhanced MRI, *MRI* magnetic resonance imaging, *CT* computed tomography, *MDCT* multiple detector CT

Discussion {#Sec11}
==========

This study analysed the cost impact of three different imaging strategies (Gd-EOB-DTPA-MRI, ECCM-MRI, CE-MDCT) in the evaluation of patients with confirmed or suspected CRCLM. In almost all scenarios, the cost of diagnostic workup was lower when Gd-EOB-DTPA-MRI was used as the initial imaging procedure compared with other strategies, despite it being the more expensive imaging modality compared with ECCM-MRI and CE-MDCT. This was due to the fact that no patient in the Gd-EOB-DTPA-MRI group required additional imaging for a treatment decision, compared to 18.1 % and 39.7 % of the safety population in the ECCM-MRI and CE-MDCT groups, respectively.

Gd-EOB-DTPA-MRI as the initial imaging procedure resulted in the detection of CRCLM in significantly more patients, offering more patients a more definitive assessment and, in suitable candidates, potential curative treatment. This result is in line with previous studies, which demonstrated the superior sensitivity of Gd-EOB-DTPA-MRI to detect liver metastasis \[[@CR12]--[@CR14], [@CR21]--[@CR23]\]. The observation that a higher percentage of patients in the group where Gd-EOB-DTPA-MRI was the initial imaging procedure were assessed as eligible for surgery, compared to the other two groups, was particularly interesting. A possible explanation could be that the higher confidence in the pre-operative imaging stimulated bolder treatment decisions, especially regarding more aggressive surgical approaches. Methodologically we can rule out a bias due to the centrally organized randomization procedure as described in the methods part as well as an improper randomization with regard to patients mean age, presence of non-assessable lesions, number of affected segments, and total number of lesions (Supplemental Table [3](#MOESM3){ref-type="media"}). Any unknown bias, however, cannot be ruled out completely. Moreover, the decisions regarding eligibility for surgery were made locally in the centres and thus influenced by the local expertise.

Cost calculations must be considered in the context of the relevant endpoints and interpreted with reference to the ultimate goals of imaging in patients with CRCLM: sensitive detection, accurate staging and correctly identifying patients that can be offered potentially curative intervention. Interestingly enough, the main driver of cost in our study was not cost of imaging or contrast media, but cost of surgery. As more patients in the Gd-EOB-DTPA-MRI group underwent surgery, the total cost of surgery was higher in this group. This fact should not be interpreted in the sense that Gd-EOB-DTPA-MRI generates higher health-care costs, but that it better fulfils the ultimate goals of imaging as mentioned above. Even if patients cannot be operated on directly, but can be resected only after a downsizing pre-operative chemotherapy, the detailed knowledge of the initial findings seems to be of high relevance to prevent local hepatic recurrences \[[@CR21], [@CR23]\].

The calculations were undertaken for several countries with varied health-care systems and different levels of health resources and spending, including resource-challenged countries, lending strength to the results. Furthermore, rather than using protocol-defined clinical routines, regional differences in the compilation of multidisciplinary treatment conference teams were accounted for, making the findings more robust in terms of real-life clinical practice. Although there were huge differences in the reimbursement systems and unit costs, the general outcome in the different countries was quite uniform.

From a patient perspective, the eligibility for surgery for liver metastases represents a favourable event, changing often from an initially assumed incurable situation to a potentially curable situation, associated with a good chance of long-term survival. From a hospital perspective, with reimbursement systems in place in most countries, the higher costs are likely to be covered by the higher revenue from the medical procedures undertaken. Furthermore, from a health-care provider perspective, the costs need to be weighed against the mid- and long-term clinical and economic benefits of the potentially life-preserving surgery. Potential advantages in the management of surgical candidates may even increase the economic benefit of a strategy starting with Gd-EOB-DTPA-MRI, as the need for an additional imaging procedure after initial unequivocal imaging findings may defer some treatments.

The results of this study are consistent with results from a previously published health economic model that was designed to estimate the aggregated costs of three different imaging strategies in patients with metachronous CRCLM \[[@CR20]\]. In that study, data collected from a Delphi panel composed of 13 pairs of clinical experts using a decision-tree model, estimated probabilities for the need of further imaging to come to a treatment decision. Applying actual clinical data to the model from diverse clinical practices due to the multinational nature of the VALUE trial, the performance of Gd-EOB-DTPA-MRI was better in the clinical trial than predicted in the health economic model (actual need for further imaging 0 % compared to 8.6 % in the model). Specifically, the prediction that fewer examinations may lead to cost savings in the strategy starting with Gd-EOB-DTPA-MRI has been confirmed by the clinical study data.

The main limitation of this study was the lack of follow-up of patients. The long-term clinical and economic impact of each diagnostic strategy can therefore not be estimated. The measurement of cost for the different imaging strategies go far beyond the endpoints used in this paper. The performance of the imaging is likely to affect health-care costs in patients until the time of death or confirmation of a cure. For example, in patients where curative intended treatment was initiated too late due to a delay in diagnosis related to suboptimal imaging, the cost of palliative measures has to be measured against the cost of possible curative surgery. Likewise, tumour recurrence as the result of suboptimal imaging in patients undergoing curative-intended intervention will incur costs for both surgery and palliative treatment, probably without any survival advantage. It must, however, be emphasized that the cost for individual patients in terms of suffering and premature death due to failed therapeutic strategies as a result of sub-optimal imaging is immeasurable.

In conclusion, the cost of the diagnostic work-up was similar in all three arms, despite the fact that Gd-EOB-DTPA-MRI is more expensive than ECCM-MRI and CE-MDCT, due to the fact that patients randomized to Gd-EOB-DTPA-MRI did not require additional imaging. The cost of surgery was higher in the Gd-EOB-DTPA-MRI group, as significantly more patients underwent surgery; however, this has to be regarded in the sense that Gd-EOB-DTPA-MRI better fulfils the ultimate goals of imaging to identify suitable patients for liver surgery, thereby offering them a curative approach.
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